Provided by Tiger Trade Technology Pte. Ltd.

X4 Pharmaceuticals Inc

3.64
+0.04231.18%
Volume:237.30K
Turnover:854.96K
Market Cap:361.12M
PE:-4.11
High:3.66
Open:3.60
Low:3.44
Close:3.60
52wk High:4.83
52wk Low:2.80
Shares:99.15M
Float Shares:62.35M
Volume Ratio:7.63
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8867
EPS(LYR):-1.8726
ROE:-113.08%
ROA:-28.15%
PB:2.32
PE(LYR):-1.95

Loading ...

X4 Pharmaceuticals Down over 13%, on Track for Largest Percent Decrease Since June 2025

Dow Jones
·
Yesterday

X4 Pharmaceuticals Says FDA Backs Reduced Enrollment Target for 4WARD Phase 3 Chronic Neutropenia Trial

Reuters
·
Sep 08

X4 Pharmaceuticals - FDA Indicates Proposed Safety Database Acceptable for Potential Snda

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals - FDA Agrees to Reduced Sample Size for 4Ward Phase 3 Trial

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals - 4Ward Trial Enrollment Expected to Complete by Year-End 2026; Topline Data in H1 2028

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

THOMSON REUTERS
·
Sep 08

X4 Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Sep 02

X4 Pharmaceuticals Grants New Hires Options for 50,000 Shares at $4.04 Each

Reuters
·
Sep 02

X4 Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 07

X4 Pharmaceuticals Q2 EPS $(0.13) Beats $(0.18) Estimate, Sales $8.806M Beat $2.420M Estimate

Benzinga Earnings
·
Aug 07

X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million

Reuters
·
Aug 07

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
Aug 07

X4 Pharmaceuticals Inc Expected to Post a Loss of 18 Cents a Share - Earnings Preview

Reuters
·
Aug 05

X4 Pharmaceuticals Issues Inducement Stock Options for 12,000 Shares at $3.98 Each

Reuters
·
Aug 04

X4 Pharmaceuticals Inc : Wells Fargo Initiates Coverage with Overweight Rating; Price Target $11

THOMSON REUTERS
·
Jul 10

X4 Pharmaceuticals Issues Inducement Stock Options for 750,000 Shares at $4.03 Each

Reuters
·
Jul 08

X4 Pharmaceuticals Director Kelly Gold Files Initial Beneficial Ownership Statement

Reuters
·
Jul 02

Press Release: X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to Its Board of Directors

Dow Jones
·
Jul 01

X4 Pharmaceuticals Initiated at Outperform by Leerink Partners

Dow Jones
·
Jun 02

X4 Pharmaceuticals initiated with an Outperform at Leerink

TIPRANKS
·
Jun 02